Effect of risedronate on bone mass, remodelling and biomechanical strength in orchidectomized rats
Effect of risedronate on bone mass, remodelling and biomechanical strength in orchidectomized rats
复制标题
DOI：
10.1159/000139151
复制
发表时间：
2008-01-01
期刊：
影响因子：
--
通讯作者：
Phipps, R. J.
中科院分区：
文献类型：
--
作者：
Diaz-Curiel, M.;de la Piedra, C.;Phipps, R. J.
背景：研究了利塞膦酸钠预防和/或治疗雄性大鼠腰椎切除术诱导的骨质疏松症的能力。方法：95只10周龄雄性Wistar大鼠，分别行假手术和双侧睾丸切除。预防研究：Sham：假手术大鼠; ORX：去卵巢大鼠; ORX + RSD：去卵巢大鼠，用利塞膦酸盐治疗6周。手术后6周处死动物。治疗研究：假手术1和ORX 1：假手术和腰椎切除大鼠在腰椎切除术后3个月处死;假手术2、ORX 2和ORX 2 + RSD：假手术和腰椎切除大鼠在腰椎切除术后3个月开始用安慰剂或利塞膦酸钠治疗6周，然后处死。利塞膦酸盐（0.5 mg/kg/天）和安慰剂（生理盐水）通过经口灌胃给药。处死后测定骨密度（DEXA）、骨体积（BV/TV）、骨钙素（BGP）和血清I型胶原羧基端肽（CTX）。进行了股骨低速扭转测试。结果：睾丸切除术导致骨重建增加，BV/TV丢失，对扭转强度无影响。利塞膦酸钠治疗部分防止了这些影响。在治疗研究中，利塞膦酸钠减少了骨重建，并将BV/TV恢复到高于假手术组的水平，改善了生物力学参数。结论：利塞膦酸钠可用于预防或治疗男性性腺功能减退所致的骨质疏松症。版权所有（C）2008 S. Karger AG，巴塞尔。
Background: The ability of risedronate to prevent and/or treat orchidectomy-induced osteoporosis in male rats was studied. Methods: Ninety-five 10-week- old male Wistar rats were sham-operated or orchidectomized. Prevention study: Sham: sham-operated rats; ORX: orchidectomized rats; ORX + RSD: orchidectomized rats, treated for 6 weeks with risedronate. Animals were sacrificed 6 weeks after surgery. Treatment study: Sham 1 and ORX 1 : sham and orchidectomized rats sacrificed 3 months after orchidectomy; Sham 2, ORX 2 and ORX 2 + RSD: sham-operated, and orchidectomized rats treated with placebo or risedronate for 6 weeks starting 3 months after orchidectomy, and then sacrificed. Risedronate (0.5 mg/kg/day) and placebo (saline) were administered via oral gavage. After sacrifice, bone mineral density by DEXA, bone volume (BV/TV), osteocalcin (BGP), and serum carboxyterminal telopeptide of collagen type I (CTX) were measured. Femur low-rate torsion testing was performed. Results: Orchidectomy produced an increase in bone remodelling with loss of BV/TV, without effects on torsional strength. Risedronate treatment partially prevented these effects. In the treatment study, risedronate reduced bone remodelling and restored BV/TV to levels higher than those of the sham group, improving biomechanical parameters. Conclusions: These results suggest that risedronate could be used as a prevention or treatment of male osteoporosis due to hypogonadism. Copyright (C) 2008 S. Karger AG, Basel.